ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than...

Full description

Bibliographic Details
Main Authors: Irina V. Poddubnaya, Lyubov S. Al-Radi, Tatyana E. Byalik, Kamil D. Kaplanov, Valentina Z. Molostvova, Evgeniy A. Nikitin, Tatyana I. Pospelova, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik, Gayane S. Tumyan
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-05-01
Series:Современная онкология
Subjects:
chronic lymphocytic leukemia
bruton’s tyrosine kinase inhibitors
immunochemotherapy
targeted therapy
acalabrutinib
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34167/22581

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/34167/22581

Similar Items